You are here: Industry Insights > AbbVie

News List

AbbVie ends Phase III brain tumour study due to failed primary goal pharmatimes
May 21, 2019
AbbVie has ended its ongoing phase III INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in some patients with newly diagnosed glioblastoma (GBM), the most aggressive cancer that begins within the brain.
FDA greenlights Roche and AbbVie's Venclexta for chronic lymphocytic leukaemia pharmafile
May 17, 2019
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in combination with Gazyva (obinutuzumab) for ...
AbbVie and Boehringer settle Humira biosimilar patent dispute in US pharmaceutical-technology
May 16, 2019
AbbVie and Boehringer Ingelheim have settled a patent dispute in the US over Cyltezo (adalimumab-adbm), a biosimilar of Humira (adalimumab).
Boehringer buckles in AbbVie patent fight, saving Humira from biosims until 2023 fiercepharma
May 15, 2019
Boehringer Ingelheim fought hard against AbbVie’s so-called “patent thicket” surrounding the world’s bestselling med, Humira. But in the end, the German company ended up settling, just like its fellow biosimilar makers.
AbbVie raises annual earnings guidance despite drop in Q1 sales, profit on biosimilar hit to Humira firstwordpharma
April 26, 2019
"We are off to another excellent start, including first quarter sales and earnings above expectations," remarked CEO Richard Gonzalez ...
AbbVie shakes up psoriasis field with blockbuster-to-be newcomer Skyrizi fiercepharma
April 25, 2019
Move over, Johnson & Johnson—AbbVie just joined the party with a direct competitor to Tremfya, and analysts say it might just be best-in-class.
Skyrizi gets US approval for psoriasis pharmatimes
April 24, 2019
AbbVie has announced the US Food and Drug Administration (FDA) approval of its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis.
ICER Posts Draft Scoping Document for the Assessment of Treatments for Rheumatoid Arthritis firstwordpharma
April 12, 2019
ICER Posts Draft Scoping Document for the Assessment of Treatments for Rheumatoid Arthritis.
AbbVie's massive Humira discounts are stifling Netherlands biosimilars fiercepharma
April 03, 2019
Could a drug's price ever be too low? That’s what some market-watchers are asking in the Netherlands, where AbbVie is discounting Humira as much as 89%.
Pain intensifies for AbbVie as it slashes 178 jobs from Stemcentrx fiercebiotech
March 29, 2019
It was a $6 billion deal that was meant to help bolster AbbVie’s pipeline and help wean the biopharma off its Humira reliance, but Stemcentrx has proven to be a major thorn in its side. Now, the time has come to start digging it out.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page